EP Patent

EP3868772A1 — Phosphorodiamidate backbone linkage for oligonucleotides

Assigned to Geron Corp · Expires 2021-08-25 · 5y expired

What this patent protects

This invention relates to antisense oligonucleotides comprising at least one N3'----+P5' phosphorodiamidate linkage (NPN) in the backbone as well as methods for using the same. The antisense oligonucleotides can effectively prevent or decrease protein expression.

USPTO Abstract

This invention relates to antisense oligonucleotides comprising at least one N3'----+P5' phosphorodiamidate linkage (NPN) in the backbone as well as methods for using the same. The antisense oligonucleotides can effectively prevent or decrease protein expression.

Drugs covered by this patent

Patent Metadata

Patent number
EP3868772A1
Jurisdiction
EP
Classification
—
Expires
2021-08-25
Drug substance claim
No
Drug product claim
No
Assignee
Geron Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.